Burning Rock’s US stock surges after $223m IPO prices high

Jonathan Breen

June 15, 2020 08:15 am

WallSt_Adobe_575x375_12June2020 — Close up of a Wall street direction sign, New York City, vintage process | Delphine Poggianti/Delphotostock - stock.adobe.com

Burning Rock Biotech, a Chinese cancer treatment firm, raised $222.8m from its US listing last Friday. The issuer's stock soared nearly 50% on its debut, after the IPO was priced above the initial guidance.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOs Health and Biotech Equity China Americas Asia Greater China Northeast Asia Asia Pacific United States Emerging Markets North America SRI

JB

Jonathan Breen

Equities editor GlobalCapital Asia